26 articles for A Casimiro-Garcia
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.

Pfizer
Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.

Pfizer
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.

Pfizer
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.

Pfizer
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.

Pfizer
Chemical tools for the Gid4 subunit of the human E3 ligase C-terminal to LisH (CTLH) degradation complex.

University of Toronto
Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1.

Pfizer
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.

Pfizer
Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.

Pfizer
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.

Purdue University
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.

Pfizer
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.

Pfizer
Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.

Pfizer
BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS

Lycia Therapeutics
COMPOUNDS AND METHODS FOR MODULATING FXR

Terns Pharmaceuticals
Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition

Optikira
Inhibitors of bruton's tyrosine kinase

Hoffmann-La Roche
Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics

King Abdulaziz University
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

Boehringer Ingelheim International
bis-Pyridazine compounds and their use in treating cancer

Astrazeneca
Substituted acethydrazide derivative, preparation method and use thereof

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Toll-like receptor 2-agonistic lipopeptides, and method of making the same

University of Kansas
Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds

Array Biopharma
Effects of novel human cathepsin S inhibitors on cell migration in human cancer cells.

National Tsing Hua University
Overview of the SAMPL5 host-guest challenge: Are we doing better?

University of California San Diego
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

Glaxosmithkline